<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04657887</url>
  </required_header>
  <id_info>
    <org_study_id>OPALE study</org_study_id>
    <nct_id>NCT04657887</nct_id>
  </id_info>
  <brief_title>Registry of Patients With Von WilLEbrand Disease Treated With Voncento®</brief_title>
  <acronym>OPALE</acronym>
  <official_title>Observational Registry of Patients With Von WilLEbrand Disease Treated With Voncento®</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSL Behring</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSL Behring</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Description of the long-term evolution of patients with von Willebrand disease and treated&#xD;
      with Voncento® and of the hemostatic efficacy in the prevention and the treatment of&#xD;
      non-surgical bleeding episodes and prevention of surgical bleeding during 2 years after&#xD;
      patient inclusion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inherited von Willebrand disease (VWD) is considered the most common bleeding disorder. Its&#xD;
      prevalence is approximately 1% in the general population but symptomatic patients are rarer&#xD;
      (0.01%). It is caused by a partial or total quantitative deficiency (type 1 and type 3) or by&#xD;
      a qualitative defect (type 2) of von Willebrand factor (VWF), a large multimeric protein that&#xD;
      is required for platelet adhesion and serves as factor VIII (FVIII) carrier. Type 2 VWD is&#xD;
      further divided in four subgroups (2A, 2B, 2M, and 2N) that are distinguished according to&#xD;
      the nature of the VWF defect. Most patients with type 1 VWD can be treated with the synthetic&#xD;
      vasopressin analogue desmopressin (DDAVP; 2-desamino-8-D-arginine vasopressin), whereas&#xD;
      patients with type 3 VWD and most patients with type 2 VWD require concentrates containing&#xD;
      VWF. Plasma-derived FVIII concentrates, which were initially developed for the treatment of&#xD;
      haemophilia, contain large amounts of VWF and are used in patients for whom DDAVP treatment&#xD;
      is deemed ineffective or contraindicated. Voncento® (CSL Behring) is a plasma-derived&#xD;
      FVIII/VWF concentrate registered in France since 2015 for the treatment and prevention of&#xD;
      bleeding events in patients with inherited VWD. OPALE is an observational study describing&#xD;
      the use of human coagulation FVIII/VWF concentrate (Voncento®) to treat and prevent bleeding&#xD;
      episodes in a French cohort of patients with inherited von Willebrand disease in the real&#xD;
      life settings. The aim of the OPALE study is to describe the efficacy and the safety of&#xD;
      Voncento® in the prophylaxis and treatment of haemorrhage or surgical bleeding.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 23, 2015</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Global assessment by the patient and the investigator of the hemostatic efficacy of Voncento® in the management of non-surgical bleeding episodes</measure>
    <time_frame>Up to 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of non-surgical bleeding episodes per year</measure>
    <time_frame>Up to 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of administrations of Voncento® needed to treat a non-surgical bleeding episode and for the long term prophylaxis</measure>
    <time_frame>Up to 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total dose of Voncento® (in IU/kg of VWF) needed to treat a non-surgical bleeding episode and for the long term prophylaxis</measure>
    <time_frame>Up to 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment by the investigator of the hemostatic efficacy of Voncento® during the treatment and the prophylaxis of surgical bleedings and after surgical procedures</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of administrations of Voncento® needed to prevent or treat surgical bleeding episode</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total dose of Voncento® (in IU/kg of VWF) needed to prevent or treat surgical bleeding episode</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nature and impact of adverse events and in particular serious adverse events, adverse events related to Voncento®</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Collection of available biological data (ex: FVIII, VWF:Rco, VWF:Ag)</measure>
    <time_frame>At baseline and up to 24 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Von Willebrand Disease</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Voncento®</intervention_name>
    <description>Solution for injection</description>
    <other_name>Biostate</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        French cohort of patients with inherited von Willebrand disease treated with Voncento.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients suffering from constitutional von Willebrand disease for whom Desmopressin&#xD;
             treatment is deemed ineffective or contraindicated&#xD;
&#xD;
          -  Patients suffering from von Willebrand disease and being treated or having been&#xD;
             treated with Voncento® for the treatment of surgical and non-surgical bleeding&#xD;
             episodes, the prophylaxis of surgical and non-surgical bleedings&#xD;
&#xD;
          -  Patients with no history or suspicion of inhibitors (judged on previous efficacy)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refusal of the patient or the patient's legal representative to take part in the&#xD;
             study;&#xD;
&#xD;
          -  Existence of a contraindication to the use of Voncento® treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>CSL Behring SA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trial Registration Coordinator</last_name>
    <phone>610-878-4000</phone>
    <email>clinicaltrials@cslbehring.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Besançon</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Morvan Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Lyon</name>
      <address>
        <city>Bron</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Caen</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Simone Veil</name>
      <address>
        <city>Eaubonne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Mignot</name>
      <address>
        <city>Le Chesnay</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Bicêtre</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Eloi</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHRU Nancy</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Lariboisière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Rouen</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 1, 2020</study_first_submitted>
  <study_first_submitted_qc>December 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2020</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vWD</keyword>
  <keyword>von Willebrand Factor</keyword>
  <keyword>vWF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Von Willebrand Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

